Austin, TX, July 15, 2004 - As reported today in the New England Journal of Medicine, Cenetron served as the international central laboratory in a clinical trial of Peginterferon Alfa-2a plus Ribavirin for chronic hepatitis C virus infection in HIV-infected patients. This study was conducted by the AIDS Pegasys Ribavirin International Coinfection Trial (APRICOT) study group.
The study examined 868 persons who were infected with both HIV and HCV and who had not previously been treated with interferon or ribavirin were randomly assigned to receive one of three regimens: 1) peginterferon alfa-2a plus ribavirin, 2) peginterferon alfa-2a plus placebo, or 3) interferon alfa-2a plus ribavirin. The primary end point was a sustained virologic response (as defined by serum HCV RNA levels) at week 72.
The study concluded that among patients infected with both HIV and HCV, the combination of peginterferon alfa-2a plus ribavirin was significantly more effective than either interferon alfa-2a plus ribavirin or peginterferon alfa-2a monotherapy.
Results were published in the New England Journal of Medicine at N Engl J Med 2004;351:43
About Cenetron Diagnostics
Cenetron Diagnostics is a premier provider of molecular laboratory services, providing support for anti-viral and oncology drug development programs, and pharmacogenomics. Founded in 1995, Cenetron has supported pivotal global trials in North and South America, Europe, Africa and the Pacific Rim. Cenetron's client list includes leading pharmaceutical clients in the United States and Europe. For further information visit www.cenetron.com
For Additional Information
Dwight DuBois, MD